Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis.
Effects of natalizumab treatment on the CSF proteome of multiple sclerosis patients.
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
Genzyme’s Lemtrada™ approved in Canada for treatment of multiple sclerosis
Phase IV Study Reports Multiple Sclerosis Success with Teriflunomide
Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.
High dose thiamine improves fatigue in multiple sclerosis.
Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
Managing fatigue in patients with multiple sclerosis.
GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40mg three-times weekly versus 20mg daily in patients with relapsing-remitting multiple sclerosis.
Early Growth Response Gene-2 Controls IL-17 Expression and Th17 Differentiation by Negatively Regulating Batf.
Amiloride HCI Tablets, USP 5 mg
High dose naltrexone for dyskinesias induced by levodopa.
Periventricular lesions help differentiate neuromyelitis optica spectrum disorders from multiple sclerosis.
Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta.
Exogenous schwann cells migrate, remyelinate and promote clinical recovery in experimental auto-immune encephalomyelitis.
Treatment of walking impairment in multiple sclerosis with dalfampridine.
Synthon obtains approval for glatiramer acetate 20 mg/mL in Europe
Sustained disability improvement is associated with T1 lesion volume shrinkage in natalizumab-treated patients with multiple sclerosis.
Flow cytometric analysis of cerebrospinal fluid samples and its usefulness in routine clinical practice.
Guidelines for the use of intravenous immunoglobulin in the treatment of neurologic diseases.
Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine).
[Diagnosis of multiple sclerosis - the 2010 revision of the McDonald criteria.]
Early signs of memory impairment among multiple sclerosis patients with clinically isolated syndrome.
The influence of HLA-DRB1*15 on motor cortical pathology in multiple sclerosis.

Pages